DNA carries genetic instructions. It is relatively stable and can reveal inherited or acquired genetic variation.
Technology overview
Two blood-based technologies.
RNA screening today. ctDNA monitoring next.
BioNexus brings together whole-blood RNA screening through MRNA Scientific and a tumor-naive ctDNA platform being prepared for ASEAN through its Fidelion relationship.
Why precision medicine matters
Healthcare is learning to read the biology beneath the symptoms.
Traditional care often begins after symptoms appear and applies knowledge derived from broad patient populations. Genomics and molecular diagnostics add another layer: measurable biological signals that can help characterize individual risk, disease and change over time.
Blood-based technologies are especially important because a blood draw can, in suitable settings, provide molecular information without a surgical tissue procedure and can be repeated to observe change. These tools complement clinical evaluation, imaging and other established methods; they do not replace them.
The molecular vocabulary
DNA, RNA, cfDNA and ctDNA
are related—but not interchangeable.
Understanding the distinction explains why the two BioNexus approaches answer different healthcare questions.
RNA helps translate genetic instructions into biological activity. Whole-blood expression patterns can provide a dynamic view of how the body is responding.
Cell-free DNA is released into the bloodstream as cells turn over. It can originate from normal tissue as well as disease processes.
Circulating tumor DNA is the portion of cfDNA shed by tumor cells. It may carry molecular changes associated with a cancer.
Key relationship: ctDNA is a subset of cfDNA. RNA-based expression screening and ctDNA-based monitoring therefore use different molecular signals for different clinical contexts.
Two technology pathways
Different signals.
Different questions.
BioNexus follows two distinct blood-based pathways. BGS reads whole-blood RNA expression to provide screening and risk information. VitaGuard™ is described in BGLC's November 2025 filed release (opens in a new tab) as using a tumor-naive approach that begins from blood without a patient-specific tumor assay.
From science to healthcare
Bringing molecular insight closer to regional care.
BioNexus is building on laboratory experience in Malaysia and relationships across Southeast Asia to evaluate how molecular technologies can be implemented responsibly.
Screening experience
MRNA Scientific provides whole-blood RNA screening and laboratory services. BGS provides screening and risk information; it is not a diagnosis.
Advance quality and evidence
BioNexus intends to evolve BGS through contemporary software, stronger quality systems and further analytical and clinical work.
Different territory, separate readiness
The technology has been commercialized as a laboratory-developed test in China. ASEAN use remains subject to local technical validation, regulatory requirements, laboratory implementation and commercial execution.
Build connected insight
Over time, repeat molecular data may support future research and analytical tools, subject to evidence, regulation, consent and responsible data use.
Molecular screening and monitoring technologies are not substitutes for professional medical advice, diagnosis or treatment. Performance, clinical utility, permitted use and availability depend on the specific test, indication and jurisdiction.
Statements on this page about plans, expectations and future events are forward-looking statements that involve risks and uncertainties, and actual results may differ materially. See the forward-looking statements notice and the risk factors in BGLC's SEC filings.